Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedInclusion criteria were standardized to 18-72 years and clarified lab and cardiac thresholds (ALT/AST ≤ 2.5× ULN; total bilirubin ≤ 1.5 mg/dL with Gilbert's syndrome exception; LVEF ≤ 45% for select patients).SummaryDifference0.5%

- Check16 days agoChange DetectedRevised the study design to include Cohort 3 with pembrolizumab and updated treatment regimens (TIL with IL-2) and dosing; added clarifications to cohort assignments and eligibility criteria.SummaryDifference0.8%

- Check24 days agoChange DetectedAdded Melanoma as a related topic and added MedlinePlus Genetics; updated the revision tag from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check31 days agoChange DetectedAdded Revision: v3.4.3; deleted Melanoma and related topics (MedlinePlus Genetics); Revision: v3.4.2.SummaryDifference0.2%

- Check38 days agoChange Detected- Melanoma added as a related topic and a MedlinePlus Genetics entry added to related topics.SummaryDifference0.1%

- Check45 days agoChange DetectedMelanoma and the related topic MedlinePlus Genetics were removed from the page.SummaryDifference0.1%

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.